QQQ   290.16 (-0.08%)
AAPL   114.66 (-2.28%)
MSFT   209.62 (-0.37%)
FB   268.56 (-0.42%)
GOOGL   1,726.31 (-0.58%)
AMZN   3,094.46 (-0.16%)
TSLA   521.75 (+6.56%)
NVDA   525.00 (+0.28%)
BABA   270.69 (-0.02%)
CGC   24.86 (+4.81%)
GE   10.11 (+3.59%)
MU   63.96 (+4.17%)
AMD   85.32 (+0.80%)
T   28.62 (+1.06%)
NIO   53.77 (+9.18%)
F   8.89 (+1.72%)
ACB   7.28 (+2.10%)
GILD   59.39 (-1.20%)
NFLX   481.12 (-1.46%)
BA   210.17 (+5.29%)
DIS   146.18 (+3.62%)
QQQ   290.16 (-0.08%)
AAPL   114.66 (-2.28%)
MSFT   209.62 (-0.37%)
FB   268.56 (-0.42%)
GOOGL   1,726.31 (-0.58%)
AMZN   3,094.46 (-0.16%)
TSLA   521.75 (+6.56%)
NVDA   525.00 (+0.28%)
BABA   270.69 (-0.02%)
CGC   24.86 (+4.81%)
GE   10.11 (+3.59%)
MU   63.96 (+4.17%)
AMD   85.32 (+0.80%)
T   28.62 (+1.06%)
NIO   53.77 (+9.18%)
F   8.89 (+1.72%)
ACB   7.28 (+2.10%)
GILD   59.39 (-1.20%)
NFLX   481.12 (-1.46%)
BA   210.17 (+5.29%)
DIS   146.18 (+3.62%)
QQQ   290.16 (-0.08%)
AAPL   114.66 (-2.28%)
MSFT   209.62 (-0.37%)
FB   268.56 (-0.42%)
GOOGL   1,726.31 (-0.58%)
AMZN   3,094.46 (-0.16%)
TSLA   521.75 (+6.56%)
NVDA   525.00 (+0.28%)
BABA   270.69 (-0.02%)
CGC   24.86 (+4.81%)
GE   10.11 (+3.59%)
MU   63.96 (+4.17%)
AMD   85.32 (+0.80%)
T   28.62 (+1.06%)
NIO   53.77 (+9.18%)
F   8.89 (+1.72%)
ACB   7.28 (+2.10%)
GILD   59.39 (-1.20%)
NFLX   481.12 (-1.46%)
BA   210.17 (+5.29%)
DIS   146.18 (+3.62%)
QQQ   290.16 (-0.08%)
AAPL   114.66 (-2.28%)
MSFT   209.62 (-0.37%)
FB   268.56 (-0.42%)
GOOGL   1,726.31 (-0.58%)
AMZN   3,094.46 (-0.16%)
TSLA   521.75 (+6.56%)
NVDA   525.00 (+0.28%)
BABA   270.69 (-0.02%)
CGC   24.86 (+4.81%)
GE   10.11 (+3.59%)
MU   63.96 (+4.17%)
AMD   85.32 (+0.80%)
T   28.62 (+1.06%)
NIO   53.77 (+9.18%)
F   8.89 (+1.72%)
ACB   7.28 (+2.10%)
GILD   59.39 (-1.20%)
NFLX   481.12 (-1.46%)
BA   210.17 (+5.29%)
DIS   146.18 (+3.62%)
Log in
NASDAQ:TGTX

TG Therapeutics Stock Forecast, Price & News

$30.71
+0.86 (+2.88 %)
(As of 11/23/2020 01:58 PM ET)
Add
Compare
Today's Range
$29.63
Now: $30.71
$31.03
50-Day Range
$25.27
MA: $28.31
$31.10
52-Week Range
$6.34
Now: $30.71
$31.97
Volume39,266 shs
Average Volume1.95 million shs
Market Capitalization$4.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.24
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and multiple sclerosis (MS). The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. It also develops Ublituximab, a novel anti-CD20 monoclonal antibody, which is in Phase III pivotal study for the treatment of CLL and MS; Umbralisib, a dual PI3K delta and CK1 epsilon inhibitor, which is in Phase III pivotal study for the treatment of CLL, and Phase 2b pivotal study for the treatment of marginal zone lymphoma and follicular lymphoma. In addition, the company develops TG-1501, an anti-PD-L1 monoclonal antibody, which is in Phase I pivotal study for the treatment of B-cell cancers; TG-1701, an oral Bruton's Tyrosine Kinase, which is in Phase I pivotal study for the treatment of B-cell cancers; and TG-1801, an anti-CD47/CD19 bispecific antibody that is in Phase I pivotal study for the treatment of B-cell cancers. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Read More
TG Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484
Employees176

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Price / Sales26,920.39
Book Value$0.39 per share

Profitability

Net Income$-172,870,000.00
Net Margins-135,198.03%

Miscellaneous

Market Cap$4.04 billion
Next Earnings Date3/2/2021 (Estimated)
OptionableOptionable
$30.71
+0.86 (+2.88 %)
(As of 11/23/2020 01:58 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

How has TG Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TGTX stock has increased by 208.1% and is now trading at $30.84.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of TG Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TG Therapeutics
.

What stocks does MarketBeat like better than TG Therapeutics?

Wall Street analysts have given TG Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TG Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for TG Therapeutics
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) released its quarterly earnings results on Monday, November, 9th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.32. TG Therapeutics had a negative net margin of 135,198.03% and a negative return on equity of 384.84%.
View TG Therapeutics' earnings history
.

What price target have analysts set for TGTX?

5 Wall Street analysts have issued twelve-month price objectives for TG Therapeutics' shares. Their forecasts range from $37.00 to $60.00. On average, they expect TG Therapeutics' share price to reach $44.20 in the next year. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for TG Therapeutics
.

Who are some of TG Therapeutics' key competitors?

What other stocks do shareholders of TG Therapeutics own?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the following people:
  • Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 54, Pay $827.54k)
  • Mr. Sean A. Power CPA, CPA, CFO, Corp. Sec. & Treasurer (Age 38, Pay $470.56k)
  • Dr. Owen A. O'Connor, Chief Scientific Officer
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.07%), Lord Abbett & CO. LLC (3.95%), State Street Corp (3.24%), Alkeon Capital Management LLC (2.11%), Logos Global Management LP (1.33%) and Great Point Partners LLC (1.22%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Ra Capital Management, LP, Sean A Power and William James Kennedy.
View institutional ownership trends for TG Therapeutics
.

Which institutional investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, State Street Corp, Sofinnova Investments Inc., Federated Hermes Inc., Virginia Retirement Systems ET AL, Candriam Luxembourg S.C.A., UBS Asset Management Americas Inc., and First Trust Advisors LP. Company insiders that have sold TG Therapeutics company stock in the last year include Ra Capital Management, LP, and William James Kennedy.
View insider buying and selling activity for TG Therapeutics
.

Which institutional investors are buying TG Therapeutics stock?

TGTX stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Logos Global Management LP, BlackRock Inc., Alkeon Capital Management LLC, Lion Point Capital LP, Castleark Management LLC, Swiss National Bank, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for TG Therapeutics
.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $30.84.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $4.06 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-172,870,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. TG Therapeutics employs 176 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is www.tgtherapeutics.com.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.